Biograil Growth

Copenhagen-based biotech startup Biograil has raised a €20 million ($21.6 million) follow-on growth round backed by Verve Ventures, Megatrend Invest, and High-Tech Gründerfonds (HTGF) via its HTGF Opportunity fund. Building on a 2019 seed round and an initial €8.5 million close in July 2025, this milestone supports the development of the company's BIONDD technology—a standard double-zero or single-zero capsule designed as an oral alternative to injectable biologics. Biograil will use the funds to execute non-clinical GLP studies, establish GMP manufacturing processes, and initiate Phase 1 clinical trials ahead of a targeted larger financing round in 2027.